Other Information
−Removed: (c) During the three months ended March 31, 2025, the following officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) of our Company adopted a prearranged trading plan relating to our common stock and intended to satisfy the affirmative defense of Rule 10b5–1(c) under the Securities Exchange Act of 1934:
−Removed: Thomas Tray , our Vice President, Chief Accounting Officer , adopted a trading plan on February 28, 2025 providing for the sale of up to an aggregate of 1,614 shares of our common stock until February 28, 2026 .
−Removed: During the three months ended March 31, 2025, no director or officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) of our Company adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities, whether or not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), other than as set forth above.
+Added: (c) During the three months ended June 30, 2025, no director or officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) of our Company adopted a prearranged trading plan relating to our common stock and intended to satisfy the affirmative defense of Rule 10b5–1(c) under the Securities Exchange Act of 1934:
+Added: During the three months ended June 30, 2025, no director or officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) of our Company adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities, whether or not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), other than as set forth above.
Number Description of Document
−Removed: 10.1* Extension, dated as of March 12, 2025, to the Amendment, dated as of March 20, 2020, to the Collaboration and License Agreement entered into as of November 24, 2009, by and between the Company and Novartis International Pharmaceutical Ltd.
+Added: 10.1# Incyte Corporation Amended and Restated 2010 Stock Incentive Plan, as amended on April 11, 2025 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed June 11, 2025).
+Added: 10.2# 1997 Employee Stock Purchase Plan of Incyte Corporation, as amended on April 11, 2025.
+Added: (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed June 11, 2025).
+Added: 10.3# Transition Agreement between the Company and Hervé Hoppenot dated as of June 26, 2025 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed June 27, 2025).
+Added: 10.4#† Offer of Employment Letter, dated June 23, 2025, from the Company to William J.
+Added: Meury (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed June 27, 2025).
+Added: 10.5# Employment Agreement between the Company and William J.
+Added: Meury dated as of June 26, 2025 (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed June 27, 2025).
+Added: 10.6# Incyte Corporation 2024 Inducement Stock Incentive Plan, as amended on June 25, 2025 (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed June 27, 2025).
31.1* Rule 13a-14(a) Certification of Chief Executive Officer .
17 unchanged sentences
# Indicates management contract or compensatory plan or arrangement.
+Added: † Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
INCYTE CORPORATION
−Removed: April 29, 2025
−Removed: /s/ HERVÉ HOPPENOT
−Removed: Hervé Hoppenot
+Added: July 29, 2025
+Added: /s/ WILLIAM J.
President, and Chief Executive Officer
(Principal Executive Officer)
−Removed: April 29, 2025
+Added: July 29, 2025
/s/ CHRISTIANA STAMOULIS
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.